DBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00 at JMP Securities

DBV Technologies (NASDAQ:DBVT - Free Report) had its price objective increased by JMP Securities from $15.00 to $21.00 in a report released on Tuesday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright raised their price target on DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 5th. Wall Street Zen raised shares of DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th.

DBV Technologies Stock Up 0.6%

Shares of DBVT traded up $0.06 during mid-day trading on Tuesday, hitting $9.35. 66,210 shares of the company's stock were exchanged, compared to its average volume of 190,684. DBV Technologies has a 52 week low of $2.20 and a 52 week high of $12.78. The stock's 50-day simple moving average is $8.27 and its 200-day simple moving average is $5.41. The firm has a market cap of $256.10 million, a price-to-earnings ratio of -2.08 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The company had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Analysts forecast that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.